Allergen peptide fragments and use thereof

Details Allergen peptide fragments and use thereof Allergen peptide fragments and use thereof

2011-04-12

2011-04-12

Rooney, Nora M (Department: 1644)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

Reexamination Certificate

active

07923209

ABSTRACT:
The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen.

REFERENCES:
patent: 4473495 (1984-09-01), Patterson
patent: 5124249 (1992-06-01), Khan et al.
patent: 5152980 (1992-10-01), Strom et al.
patent: 5723582 (1998-03-01), Ishizaka
patent: 5767075 (1998-06-01), Avruch et al.
patent: 5965709 (1999-10-01), Presta et al.
patent: 6042831 (2000-03-01), Beretta
patent: 6071522 (2000-06-01), Thomas et al.
patent: 6074673 (2000-06-01), Guillen
patent: 6395306 (2002-05-01), Cui et al.
patent: 6649166 (2003-11-01), Maillere et al.
patent: 2002/0193295 (2002-12-01), Calenoff et al.
patent: 2003/0165514 (2003-09-01), Spertini
patent: 2003/0211510 (2003-11-01), Henderson et al.
patent: 2004/0023291 (2004-02-01), Spertini
patent: 2 341 389 (2000-03-01), None
patent: WO 93/19178 (1993-09-01), None
patent: WO 99/18983 (1999-04-01), None
patent: WO99/34826 (1999-07-01), None
patent: WO 99/34826 (1999-07-01), None
patent: WO 00/15774 (2000-03-01), None
patent: WO-00/44887 (2000-08-01), None
patent: WO 01/88085 (2001-11-01), None
patent: WO 01/88085 (2001-11-01), None
Kundrot et al. ‘Which strategy for a protein crystallization project.’ Cell Mil. Life Sci. 61:525-536, 2004.
Blumenthal et al. ‘Allergens and Immunotherapy.’ 3rd edition, Marcel Decker, Inc. New York: 2004. pp. 37-50.
Attwood et al. ‘The Babel of Bioinformatics.’ Science. 290:471-473, 2000.
Larche et al. ‘Immunological mechanisms of allergen-specific immunotherapy.’ Nature Reviews 6:761-771, 2006.
Shanti et al. ‘Identification of Tropomyosin as the Major Shrimp Allergen and Characterization of Its IgE-Binding Epitopes.’ J. Immunol. 151(10):5354-5363, 1993.
Akdis et al., “Epitope-Specific T Cell Toleranace To Phosholipase A(2) in Bee Venom Immunotherapy and Recovery by IL-2 and IL-15 in Vitro,”J. Clin. Invest., 98:1676-83, 1996.
Akdis et al., “Role of Interleukin 10 in Specific Immunotherapy,”J. Clin. Invest., 102:98-106, 1998.
Bauer et al., “Modulation of the Allergic Immune Response in BALB/c Mice by Subcutaneous Injection of High Doses of the Dominant T Cell Epitope from the Major Birch Pollen Allergen Bet v 1,”Clin. Exp. Immunol., 107:536-41, 1997.
Briner et al., “Peripheral T-Cell Tolerance Induced in Naive and Primed Mice by Subcutaneous Injection of Peptides from the Major Cat Allergen Fel d I,”Proc. Natl. Acad. Sci. USA, 90:7608-12, 1993.
Casari et al., “A Method to Predict Functional Residues in Proteins,”Structural Biology, 2(2):171-178, Feb. 1995.
De Waal et al., “Direct Effects of IL-10 on Subsets of Human CD4+ T Cell Clones and Resting T Cells. Specific Inhibition of IL-2 Production and Proliferation,”J. Immunol., 150:4754-65, 1993.
Ferreira et al., “Dissection of Immunoglobulin E and T Lymphocyte Reactivity of Isoforms of the Major Birch Pollen Allergen Bet v 1: Potential Use of Hypoallergenic Isoforms for Immunotherapy,”J. Exp. Med., 183:559-609, Feb. 1996.
Ferreira et al., “Modulation of IgE Reactivity of Allergens by Site-Directed Mutagenesis: Potential Use of Hypoallergenic Variants for Immunotherapy,”The FASEB Journal, 12:231-242, Feb. 1998.
Groux et al., “Interleukin-10 Induces a Long-Term Antigen-Specific Anergic State in Human CD4+ T Cells.”J. Exp. Med., 184:19-29, 1996.
Hansen et al., “Allergen-Specific Th1 Cells Fail to Counterbalance Th2 Cell-Induced Airway Hyperreactivity but Cause Severe Airway Inflammation,”J. Clin. Invest. 103:175-83, 1999.
Haselden, et al., “Immunoglobulin E-Independent Major Histocompatibility Complex-Restricted T Cell Peptide Epitope-Induced Late Asthmatic Reactions,”J. Exp. Med., 189:1885-94, 1999.
Hoyne et al., “Regulation of House Dust Mite Responses by Intranasally Administered Peptide: Transient Activation of CD4+ T Cells Precedes the Development of Tolerance in Vivo,”Int. Immunol., 8:335-42, 1996.
Jutel, et al., “Selective Restimulation of Antigen or Allergen Preactivated T Cells Using OKT3 F(ab)(2) Results in the Secretion of TH-1 or TH-2-Like Cytokine Patterns,”Clin. Experiment. Allergy, 25:1108-17, 1995.
Kettner, et al., “IgE and T-Cell Responses to High-Molecular Weight Allergens from Bee Venom,”Clin. Experiment. Allergy, 29:394-401, 1999.
King et al., “Antibody Responses to Bee Melittin (Api m 4) and Hornet Antigen 5 (Dol m 5) in Mice Treated with the Dominant T-Cell Epitope Peptides,”J. Allerg. Clin. Immunol., 101:397-403, 1998.
Larche, “Allergen-Derived T Cell Peptides in Immunotherapy,”Revue Francaise D'Allergologie et D'Immunologie Clinique 2003 France, 43(1):59-63, 2003.
Larche, “Peptide-Based Therapeutic Vaccines for Allergic and Autoimmune Diseases,”Nat. Med., 11(4 Suppl):S69-76, 2005.
Laver et al., “Epitopes on Protein Antigens: Misconceptions and Realities,”Cell, 61:553-556, May 1990.
Lesourd et al., “Hymenoptera Venom Immunotherapy: Relationships with Specific Antibody Responses,”J. Allergy Clin. Immunol., 83:563-71, 1989.
Malvey et al., “Peripheral Immune Tolerance Blocks Clonal Expansion but Fails to Prevent the Differentiation of Th1 Cells,” J.Immunol., 161:2168-77, 1998.
Mueller, “Diagnosis and Treatment of Insect Sensitivity,”J. Asthma Res., 3:331-3, 1966.
Müller et al., “Immunotherapy with Honeybee Venom and Yellow Jacket Venom is Different Regarding Efficacy and Safety,”J. Allergy Clin. Immunol., 89:529-35, 1992.
Müller,Insect Sting Allergy: Clinical Picture, Diagnosis and Treatment, Stuttgart, New York:1990.
Müller et al., “Position Paper: Immunotherapy with Hymenoptera Venoms,”Allergy, 48(Suppl. 14):37-46, 1993.
Müller et al., “Predictive Value of Venom-Specific IgE, IgG and IgG Subclass Antibodies in Patients on Immunotherapy with Honey Bee Venom,”Allergy, 44:412-8, 1989.
Müller et al., “Type I Skin Reactivity to Native and Recombinant Phospholipase A(2) from Honeybee Venom is Similar,”J. Allerg. Clin. Immunol., 96:395-402, 1995.
Norman et al., “Treatment of Cat Allergy with T-Cell Reactive Peptides,”Am. J. Respir. Crit. Care Med., 154:1623-8, 1996.
Oldfield, et al., “Allergen-Derived T Cell Peptide-Induced Late Asthmatic Reactions Precede the Induction of Antigen-Specific Hyporesponsiveness in Atopic Allergic Asthmatic Subjects,”J. Immunol., 167:1734-9, 2001.
Oilert et al., “Prognostic Value of Immunoblotting in Patients on Immunotherapy with Hymenoptera Venom,”J. Allergy Clin. Immunol., 105:S59, Abstract 178, 2000.
Pape, et al., “Direct Evidence that Functionally Impaired CD4+ T Cells Persist in Vivo Following Induction of Peripheral Tolerance,”J. Immunol., 160:4719-29, 1998.
Punnonen, “Molecular Breeding of Allergy Vaccines and Antiallergic Cytokines,”International Archives of Allergy and Immunology, 121(3):173-182, 2000.
Roggero et al., “A Simple and Rapid Procedure for the Purification of Synthetic Polypeptides by a Combination of Affinity Chromatography and Methionine Chemistry,”FEBS Letters, 408:285-8, 1997.
Rueff et al., “Ultrarush Immunotherapy in Patents with Hymenoptera Venom Allergy,”J. Allergy Clin. Immunol., 107:928-9, 2001.
Schneider et al., “Human Monoclonal or Polyclonal Antibodies Recognize Predominantly Discontinuous Epitopes on Bee Venom Phospholipase A2,”J. Allergy Clin. Immunol., 94(1):61-70, Jul. 1994.
Smith et al., “Recombinant Allergens for Immunotherapy: A Der p2 Variant with Reduced IgE Reactivity Retains T-Cell Epitopes,”J. Allergy Clin. Immunol., 101(3):423-425, 1998.
Takai et al., Engineering of the Major House Dust Mite Allergen Der f 2 for Allergen-Specific Immunother

Affiliated with

Also associated with

Rating

Allergen peptide fragments and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Allergen peptide fragments and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Allergen peptide fragments and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2643039